A research team at the VIB-KU Leuven Center for Microbiology has developed a novel screening method to identify antimicrobial properties of volatile substances. With this assay, they tested the vapour-phase-mediated activity of 175 essential oils (EOs) and 37 EO components. Approximately half of them proved active against the most drug-resistant type of Candida. In a context of fungi showing increasing drug resistance, these findings may be useful in both medical and agricultural applications.
The research project, led by prof. Patrick Van Dijck, is rooted in the growing problem of antifungal drug resistance. Candida cells, for example, are quickly becoming tolerant to fluconazole, the most-used antifungal drug. Next to exploring experimental new techniques, scientists also seek to repurpose existing substances. Plant essential oils (EOs), metabolites obtained by steam distillation or cold citrus peel pressing, may offer interesting opportunities: they are made up of compounds that help protect the plant against microbial or herbivore attacks.
Identifying EOs and their compounds
In the VIB-KU Leuven Center for Microbiology, Adam Feyaerts gathered a collection of 175 different EOs, constituting a collection of over one thousand different small molecules. The aim was to identify biologically active compounds present in these complex mixtures. They therefore developed a new class of assay that allowed to identify new volatile substances with antifungal activities over a distance.
Prof. Patrick Van Dijck (VIB-KU Leuven): “We screened our whole collection of EOs for vapor-phase mediated antifungal activity against two human fungal pathogens, Candida albicans and Candida glabrata. Interestingly, we found that approximately half of the EOs and their compounds had vapour-phase-mediated activity against bothCandida species. Surprisingly, C. glabrata, the most drug-resistant species of the two was on average even more susceptible. In contrast, none of the currently used antifungals showed any vapour-phase-mediated activity.”
Numerous potential applications
This is now the first simple test to look for the vapor-phase-mediated antimicrobial activity of molecules. The same assay could also be used to test other biological activity. And although these findings still have to be confirmed in clinical trials, potential applications are numerous.
Co-author Adam Feyaerts (VIB-KU Leuven): “Our findings are for instance a starting point for the development of molecules that could also be used in vaporizers. After all, volatiles can access otherwise hard to reach areas. Think of possibilities such as maintaining hygiene in hospitals or treat patients with lung infections. There are agricultural options too, such as preventing post-harvest contamination or protecting crops against pests.”
The Latest on: Antifungal drug resistance
- Matinas BioPharma Appoints Jerome D. Jabbour as Chief Executive Officer and Provides Corporate Update on March 16, 2018 at 3:00 pm
... no clinical resistance has been reported to date with amphotericin B as compared to the rapidly emerging drug resistance seen in other antifungal therapies. Currently, IV-only administered amphotericin B is the only broad spectrum fungicidal available ... […]
- HelixBind awarded grant from CARB-X to accelerate development of culture-free test for bloodstream infections on March 15, 2018 at 11:35 am
The ability to identify infections and drug-resistant bacteria in a timely manner will ... Its proprietary RaPID platform provides culture-free characterization of bacterial and fungal pathogens and resistance mechanisms direct from patient specimens ... […]
- TGV Therapeutics Drug Shows Promise Against Fungal Superbugs on March 8, 2018 at 1:14 pm
C.auris can infect wounds, the bloodstream, and the urinary tract. The pathogen is extremely dangerous because itis resistant to many existing antifungal drugs. MYC-053 is TGV’s lead product candidate, and itis described as a “novel antifungal agent ... […]
- The ethics of fighting drug resistance on February 18, 2018 at 2:24 pm
Drug resistance threatens the effective treatment of a growing list of communicable diseases – from bacterial infections to viral to and fungal diseases. When people recklessly use antibiotics to fight a common cold, when farmers use antibiotics to boost ... […]
- Deadly drug-resistant fungus sparks outbreaks in UK—and it’s stalking US on August 16, 2017 at 9:15 am
Those invasive infections are often hard to halt because C. auris is unusually resistant to anti-fungal drugs. For instance, every C. auris case in the UK has shown reduced susceptibility to the first line antifungal fluconazole, and many are resistant to ... […]
- Fungal drug resistance poses a potential crisis to modern medicine, expert warns on July 5, 2017 at 3:16 am
Fungal drug resistance poses a potential crisis to modern medicine, an expert claims. Patients are dying as doctors are finding it increasingly difficult to treat even simple fungal infections as the microbial resistance crisis continues to take hold ... […]
- Drug-resistant fungal infection identified in 122 people across 7 states on May 19, 2017 at 11:35 am
WASHINGTON (WCMH) — The number of cases of a dangerous fungal infection have grown exponentially over the past 9 months, according to a field report in the Morbidity and Mortality Weekly Report issued Thursday by the US Centers for Disease Control and ... […]
- TGV-inhalonix's New Drug to Help Patients with Resistant Fungal Lung Infections on May 13, 2017 at 5:00 pm
NEW YORK, NY / ACCESSWIRE / May 14, 2017 / TGV-inhalonix, a New York drug development company behind ground-breaking Mul-1867 which gives hope to treating life-threatening, antibiotic-resistant bacterial lung infections in patients suffering from cystic ... […]
via Google News and Bing News